Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii...